BioFuse Medical Technologies, Inc. Appoints Dr. Joe Stauffer as Chairman of the Board of Directors

FOR IMMEDIATE RELEASE
Contact:
Scott Sanders, President
BioFuse Medical Technologies, Inc.
Scott.Sanders@BioFuseMedical.com

MELBOURNE, FL (January 24, 2023) – BioFuse Medical Technologies, Inc. is pleased to announce the appointment of Dr. Joe Stauffer as Chairman of the Board of Directors. Dr. Stauffer is an executive biotech physician and CEO/Founder of Alta Life Sciences, LLC., a pharmaceutical and investment advisory firm based in Sarasota, FL. He is also currently the Chief Medical Officer (CMO) of Antibe Therapeutics, a Toronto based public biotech.

Dr. Stauffer brings a wealth of experience to BioFuse Medical Technologies, Inc. with over 25 years of medical practice and clinical research experience. He has served as CMO in both public and private specialty device, pharma and biotech companies, including his role as SVP & CMO of Global Medical Operations at Ikaria where he was responsible for leading a global team of Medical Science Liaisons, Clinical Scientists and Medical Directors in support of Ikaria’s pharmaceutical and medical device portfolio. Dr. Stauffer received his medical degree from the Philadelphia College of Osteopathic Medicine and his MBA from a joint program (TRIUM) between New York University, Stern School of Business, London School of Economics (LSE) and HEC (Hautes Etudes Commerciales) School of Management in Paris.

Dr. Stauffer is a veteran of the US Navy, honorably discharged as a Lieutenant Commander after serving 10 years as a Naval Medical Officer. He practiced clinically for eight years, first as a Navy general medicine physician and then as an Anesthesiologist. He completed residency training in Anesthesiology & Critical Care Medicine at the Johns Hopkins University Hospital and remained on Adjunct faculty as Clinical Instructor/Assistant Professor at Johns Hopkins Medicine from 2000-2016.

Prior to starting his industry career at Abbott Labs as a Medical Director, Dr. Stauffer worked at the FDA as a Medical Review Officer. He has also been intimately involved with raising a total of $650M of new equity and/or deal related financing between 2010-2021 at four different companies.

“I am honored to join the BioFuse Medical Technologies team as Chairman of the Board,” said Dr. Stauffer. “It is exciting to be a part of a company that I believe is at the forefront of innovation in surgical technology, and I look forward to working with the team to bring this revolutionary technology to surgeons and patients around the world.”

“We are thrilled to have Dr. Stauffer join the BioFuse Medical Technologies team as Chairman of the Board. His extensive experience in the biotech and medical device industry, as well as his background in clinical research and regulation, will be invaluable as we continue to develop and bring our revolutionary tissue welding surgical technology to market,” said Scott Sanders, President.

BioFuse technology offers the promise of saving time and money, and better patient outcomes using novel tissue welding technology. By replacing traditional sutures and staples, the technology has the potential to improve patient recovery times and reduce healthcare costs.
To learn more about BioFuse Medical Technologies, Inc., visit biofusemedical.com.

###

About BioFuse Medical Technologies, Inc.
BioFuse Medical Technologies’ first product offering, SurgiFuse® is a new RF tissue sealing and welding technology. Using transformative technology, proven in Europe in thousands of cases, this surgical innovation replaces traditional methods of sutures, staples, and electrosurgical vessel sealing. SurgiFuse® is a platform technology that can address a broad range of clinical applications, includes a robust pipeline of products in various stages of development, solid IP protection and trade secrets.

SurgiFuse® is an advanced high-frequency electrosurgical system that incorporates a unique and proprietary way of controlling and delivering energy to and through the target tissue. In studies, SurgiFuse® tissue fusion has been shown to be stronger than mechanical closure, creates a continuous seam in the tissue, and leaves no foreign bodies behind. SurgiFuse® encompasses the proprietary use of low voltages and high currents, optimized specifically for the tissue to be fused. In addition, energy output to the tissue occurs in pulses. These computer-controlled energy pulses create optimal temperatures that unravel large molecules in the tissue and as these molecules cool, they become intertwined and create a fusion.

This technology will serve a large and growing target market of $3 billion. Market data indicates a strong and growing demand for advanced, innovative devices that facilitate evolving surgical procedural techniques and vastly improved patient outcomes. Surgeons are looking for new technology that will eliminate scars and lower leakage and infection rates.

BioFuse Medical Technologies, Inc. is privately held and interested accredited investors may learn more about investment opportunities in the Company’s 506(c) offering by visiting: biofusemedical.com.